NL-OMON42205已完成不适用
89Zr-rituximab PET/CT for detection of central nervous system lymphoma - ZoLa study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Patients who have signed informed consent
- •- Age >= 18 years
- •- MR suspicion of a primary CNS lymphoma (homogeneous contrast enhancement, low MRI ADC values).
排除标准
- •- Pregnancy
研究者
相似试验
进行中（未招募）
不适用
A new kind of scan for patients with a lymphoma in the central nervous systemcentral nervous system localized malignant lymphoma.EUCTR2015-000056-23-NLMC Utrecht
进行中（未招募）
不适用
The use of isotope-bound antibodies to visualize and subsequently treat B-cell lymphomaCD20 positive LymphomaMedDRA version: 14.0Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005474-38-BEInstitut Jules Bordet
招募中
2 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.hereditary tumor syndrome1002239610029209NFNL-OMON52411eids Universitair Medisch Centrum24
进行中（未招募）
1 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.eurofibromatosis type 2EUCTR2020-000156-35-NLeiden University Medical Center15
已完成
不适用
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot studyNL-OMON33835niversitair Medisch Centrum Groningen26